Multicenter Trial Management Unit Expands the Scope of Research at Yale
In the past, Yale investigators who led multicenter trials had to put together ad hoc study teams, relying on unconnected siloed services to carry out their research. At the end of these trials, these teams, which had compiled so much experience and knowledge, disbanded and their knowledge was lost. This system was inefficient and put Yale at a disadvantage when competing with other institutions for grants for multicenter studies.
High PECAM-1 Levels in PAH May Predict Treprostinil Response
Results from a post hoc biomarker analysis of the FREEDOM-C2 study show high levels of platelet endothelial cell adhesion molecule 1 (PECAM-1) are associated with less improvement in 6-minute walk distance (6MWD) and may also be predictive of response to treprostinil therapy.Source: Pulmonology Advisor
Two Small RNA Molecules Can Help Diagnose Endometriosis, Study Shows
Researchers have shown that two biomarkers initially described by researchers at the Yale School of Medicine are found in increased levels in patients with surgically confirmed endometriosis when compared with patients who have other benign gynecologic conditions.Source: Endometriosis News